Potential strategies to overcome the aforementioned ADC resistance mechanisms include the development of ADCs targeting novel antigens to expand the target repertoire (e.g., TROP-2, c-Met)117; the utilization of bispecific ADCs capable of simultaneously engaging two tumor antigens to mitigate resistance caused by single-antigen loss (114); and combination therapies with targeted agents, such as proteasome inhibitors, to prevent degradation of the target protein (24). Here, TACSTD2 is linked to neoplasm.